| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| P2093 | author name string | Mulé JJ | |
| Ettinghausen SE | |||
| Lipford EH 3rd | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3623-3635 | |
| P577 | publication date | 1985-11-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells | |
| P478 | volume | 135 |
| Q36028954 | Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2 |
| Q55369043 | Combination treatment with irritant and recombinant interleukin 2 in the peritoneal cavity for evoking effective anti-tumor activity: generation of lymphokine-activated killer cells and tumor-specific killer cells. |
| Q69186911 | Combined effects of interferon alpha and interleukin 2 on the induction of a vascular leak syndrome in mice |
| Q68353306 | Differential effects of various cytokines on the generation of rat LAK cells from their purified precursors |
| Q45833763 | Effect of recombinant human interleukin 2 on the growth of a BALB/c sarcoma induced by Moloney murine sarcoma virus |
| Q69742007 | Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells |
| Q72374056 | Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2 |
| Q69735777 | Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs |
| Q68810811 | Inhibition of in vitro LAK generation by OK-432 |
| Q53076079 | Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option? |
| Q41909914 | Leucocyte interactions with the mouse cremaster muscle microcirculation in vivo in response to tumour-conditioned medium |
| Q44271867 | Lysosome rich cells contain the lytic activity of lymphokine-activated killer cell populations |
| Q90218846 | Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation |
| Q70404929 | Modulation of intestinal immune reactivity by interleukin 2. Phenotypic and functional analysis of lymphokine-activated killer cells from human intestinal mucosa |
| Q37714783 | Passive immunotherapeutic strategies for the treatment of malignant gliomas. |
| Q54279247 | Potentiated lymphokine-activated killer cell activity generated by low-dose interleukin-2 and mismatched double-stranded RNA. |
| Q35981338 | Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies |
| Q68810808 | Recruitment of inflammatory cells to a tumor deposit potentiates the immunotherapeutic effects of interleukin-2 |
| Q36356148 | Studies of lymphokine-activated killer (LAK) cells. I. Evidence using novel monoclonal antibodies that most human LAK precursor cells share a common surface marker |
| Q39737942 | The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. |
| Q68822512 | The anti-tumour efficacy of human recombinant interleukin 2. Correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo |
| Q39512710 | The development of new immunotherapies for the treatment of cancer using interleukin-2. A review |
| Q36431655 | Trafficking of activated lymphocytes into the RENCA tumour microcirculation in vivo in mice |
| Q54334291 | Trial of anticancer immunotherapy with immobilized pokeweed mitogen: immunotherapy by extracorporeal circulation. |
Search more.